Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Promethazine
Drug ID BADD_D01854
Description Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946.[A189901] Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]
Indications and Usage For the treatment of allergic disorders, and nausea/vomiting.
Marketing Status Prescription; Discontinued
ATC Code D04AA10; R06AD02
DrugBank ID DB01069
KEGG ID D00494
MeSH ID D011398
PubChem ID 4927
TTD Drug ID D0T2XU
NDC Product Code 65162-678; 54348-117
Synonyms Promethazine | Prometazin | Proazamine | Rumergan | Diprazin | Isopromethazine | Phenergan | Phenargan | Phensedyl | Pipolfen | Pipolphen | Promet | Promethazine Hydrochloride | Hydrochloride, Promethazine | Prothazin | Pyrethia | Remsed | Atosil | Diphergan
Chemical Information
Molecular Formula C17H20N2S
CAS Registry Number 60-87-7
SMILES CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Heart disease congenital03.07.07.001; 02.01.01.0090.000726%Not Available
Heart rate increased13.14.04.0020.004177%Not Available
Hemiparesis17.01.04.0010.002785%
Hepatocellular injury09.01.07.0080.002785%Not Available
Hyperacusis17.04.03.003; 04.02.02.0010.002785%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.0280.008354%
Hypersensitivity10.01.03.0030.005569%
Hypertension24.08.02.001--
Hypopnoea22.02.01.0210.012531%Not Available
Hypotension24.06.03.0020.006962%
Hypoxia22.02.02.0030.002785%
Incoherent17.02.08.002; 19.10.03.0060.004177%Not Available
Inflammatory bowel disease07.08.01.0160.002785%Not Available
Injection site phlebitis24.05.03.003; 12.07.03.012; 08.02.03.011--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia17.15.03.002; 19.02.01.002--
Intentional self-injury19.12.01.002; 12.01.08.0360.084931%Not Available
Irritability08.01.03.011; 19.04.02.013--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Jaundice cholestatic09.01.01.005--Not Available
Joint swelling15.01.02.0040.002785%Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.011138%
Leukocytosis01.02.01.0020.004177%
Leukopenia01.02.02.001--Not Available
Loss of consciousness17.02.04.0040.005569%Not Available
Lung disorder22.02.07.0010.002785%Not Available
Malaise08.01.01.003--
Memory impairment17.03.02.003; 19.20.01.0030.004177%
Muscle rigidity17.05.02.005; 15.05.04.0010.004177%Not Available
Muscle spasms15.05.03.0040.008354%
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages